RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immunovia AB (publ) - Stock

Immunovia AB (publ) Employees 2024

Immunovia AB (publ) Employees

67

Ticker

IMMNOV.ST

ISIN

SE0006091997

WKN

A2AG0F

In 2024, Immunovia AB (publ) employed 67 people, a 0% change from the 67 number of employees in the previous year.

Immunovia AB (publ) Aktienanalyse

What does Immunovia AB (publ) do?

Immunovia AB (publ) is a leading company in cancer diagnostics based in Lund, Sweden. Founded in 2007 by a group of scientists and entrepreneurs, the company specializes in the development, production, and marketing of diagnostic tests. Immunovia aims to develop innovative and reliable methods for early cancer detection to improve the progress and quality of life for cancer patients. The company's business model is based on research and development of state-of-the-art diagnostic tests, which are distributed worldwide through a network of partners. Immunovia collaborates closely with academic institutions, medical centers, and hospitals to promote research activities and conduct clinical studies. The company's goal is to develop biomarker-based tests for early cancer detection to increase patient survival rates. Immunovia operates in various fields, including pancreatic cancer diagnosis, colorectal cancer diagnosis, lupus diagnosis, and general cancer diagnostics. The company has developed products based on its diagnostic tests, such as the IMMray™ PanCan-d Test for pancreatic cancer diagnosis, IMMray™ Colon Test for colorectal cancer diagnosis, IMMray™ Lupus Test for lupus diagnosis, and IMMray™ Cancer-Screening Test for general cancer diagnostics. Immunovia actively collaborates with various partners, including strategic partnerships with leading biotechnology and pharmaceutical actors, to develop advanced diagnostic products. The company also has a strong financial base to fund its research activities and clinical studies. Overall, Immunovia is dedicated to developing innovative diagnostic tests for early cancer detection and is considered one of the leading players in the cancer diagnostics industry. Immunovia AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Immunovia AB (publ)'s Employee Base

Immunovia AB (publ)'s employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Immunovia AB (publ)'s operational capacity and future potential.

Year-to-Year Comparison

Assessing Immunovia AB (publ)'s employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Immunovia AB (publ)'s employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Immunovia AB (publ)’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Immunovia AB (publ) Stock

How many employees does Immunovia AB (publ) have this year?

Immunovia AB (publ) has 67 undefined employees this year.

How many employees did Immunovia AB (publ) have compared to the previous year?

Compared to the previous year, Immunovia AB (publ) had 0% more employees.

What impact did the number of employees have on the company Immunovia AB (publ)?

The number of employees has a direct impact on the efficiency and productivity of Immunovia AB (publ). A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Immunovia AB (publ)?

The number of employees can also have an impact on investors of Immunovia AB (publ), as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Immunovia AB (publ) affect the company?

An increase in equity of Immunovia AB (publ) can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Immunovia AB (publ)'s equity affect the company?

A reduction in equity of Immunovia AB (publ) can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Immunovia AB (publ)?

Some factors that can influence the equity of Immunovia AB (publ) include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Immunovia AB (publ) so important for investors?

The equity of Immunovia AB (publ) is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Immunovia AB (publ) influence the company?

The number of employees at Immunovia AB (publ) can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Immunovia AB (publ) evolved in recent years?

In recent years, the number of employees at Immunovia AB (publ) has changed by 0.

How many employees does Immunovia AB (publ) currently have?

Immunovia AB (publ) currently has 67 undefined employees.

Why is the number of employees important for investors of Immunovia AB (publ)?

The number of employees is important for investors of Immunovia AB (publ) as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Immunovia AB (publ) take to change the number of employees?

To change the number of employees, Immunovia AB (publ) can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Immunovia AB (publ) pay?

Over the past 12 months, Immunovia AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunovia AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Immunovia AB (publ)?

The current dividend yield of Immunovia AB (publ) is .

When does Immunovia AB (publ) pay dividends?

Immunovia AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunovia AB (publ)?

Immunovia AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Immunovia AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunovia AB (publ) located?

Immunovia AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunovia AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunovia AB (publ) from 7/2/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.

When did Immunovia AB (publ) pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Immunovia AB (publ) in the year 2023?

In the year 2023, Immunovia AB (publ) distributed 0 SEK as dividends.

In which currency does Immunovia AB (publ) pay out the dividend?

The dividends of Immunovia AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunovia AB (publ)

Our stock analysis for Immunovia AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunovia AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.